1. Home
  2. Stocks
  3. Balpharma Share Price

BAL PHARMA

Small Cap BSE: 524824 NSE: BALPHARMA
₹88.7
1 (1.14%)
As on 27 November, 2022 | 13:32
Announcements

Bal Pharma Share Price

Bal Pharma Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in BAL PHARMA

Start SIP
Share Returns Investment Rating Financials
More
Technicals Resistance and Support Delivery and Volume Result Highlights Synopsis Corporate Action MF Shareholding Similar Stocks News FAQs

Bal Pharma Share Returns

  • Over 1 Month -4.67%
  • Over 3 Month -7.36%
  • Over 6 Month -6.88%
  • Over 1 Year -13.29%

Bal Pharma Key Statistics

P/E Ratio 42.7
PEG Ratio -0.8
Market Cap Cr 138
Price to Book Ratio 2.4
EPS 5
Dividend 1.1
Relative Strength Index 41.42
Money Flow Index 24.19
MACD Signal -1.34
Average True Range 2.43

Bal Pharma Investment Rating

  • Master Rating:

  • Bal Pharma has an operating revenue of Rs. 288.36 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 3% needs improvement, ROE of 9% is fair but needs improvement. The company has a reasonable debt to equity of 46%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 12 which is a POOR score indicating inconsistency in earnings, a RS Rating of 22 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D- which indicates heavy supply, Group Rank of 128 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Bal Pharma Financials
IndicatorSep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021
Oper Rev Qtr Cr 75707469677170
Operating Expenses Qtr Cr 69647063616463
Operating Profit Qtr Cr 6536677
Depreciation Qtr Cr 2222222
Interest Qtr Cr 3222333
Tax Qtr Cr 000201-2
Net Profit Qtr Cr 1131324

Bal Pharma Technicals

EMA & SMA

Current Price
88.7
1 (1.14%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 90.06
  • 50 Day
  • 92.33
  • 100 Day
  • 95.42
  • 200 Day
  • 101.39
  • 20 Day
  • 90.39
  • 50 Day
  • 92.72
  • 100 Day
  • 94.89
  • 200 Day
  • 101.3

Bal Pharma Resistance and Support

PIVOT
₹87.6
Resistance
First Resistance 88.65
Second Resistance 89.6
Third Resistance 90.65
RSI 41.42
MFI 24.19
MACD Single Line -1.34
MACD -1.53
Support
First Resistance 86.65
Second Resistance 85.6
Third Resistance 84.65

Bal Pharma Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 10,650 638,574 59.96
Week 12,650 855,041 67.59
1 Month 16,562 1,226,391 74.05
6 Month 26,400 1,470,455 55.7

Bal Pharma Result Highlights

Bal Pharma Synopsis

NSE-Medical-Diversified

Bal Pharma Ltd belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 280.37 Cr. and Equity Capital is Rs. 14.82 Cr. for the Year ended 31/03/2022. Bal Pharma Ltd. is a Public Limited Listed company incorporated on 19/05/1987 and has its registered office in the State of Karnataka, India. Company’s Corporate Identification Number(CIN) is L85110KA1987PLC008368 and registration number is 008368.
Market Cap 138
Sales 287
Shares in Float 0.75
No of funds 2
Yield 1.13
Book Value 1.51
U/D Vol ratio 0.5
LTDebt / Equity 31
Alpha -0.04
Beta 1.07

Bal Pharma

Owner NameSep-22Jun-22Apr-22Mar-22
Promoters 52%52%52%
Foreign Portfolio Investors 0.2%0.3%0.3%
Individual Investors 31.48%31.45%31.3%
Others 16.32%16.25%16.4%

Bal Pharma Management

Name Designation
Mr. Shailesh D Siroya Managing Director
Mr. Himesh Virupakshaya Executive Director
Mr. Jatish Sheth Independent Director
Dr. C V Srinivas Independent Director
Ms. Nicloa Neeladri Independent Director
Mr. H S Venkatesh Additional Director
Mr. Kotian Chittananda Damodar Additional Director

Bal Pharma Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Bal Pharma Corporate Action

Date Purpose Remarks
2022-11-14 Quarterly Results & ESOP Inter alia, To convene Extra Ordinary General Meeting ( EGM ) for merger of Golden Drugs Pvt Ltd. a wholly owned subsidiary of the Company. per share(10%)Dividend
2022-08-11 Quarterly Results
2022-05-30 Audited Results & Final Dividend
2022-04-13 Preferential issue of shares
2022-03-09 Scheme of Amalgamation Inter alia consider approval of scheme of amalgamation between Bal Pharma Ltd and its wholly owned subsidiary i.e Golden Drugs Private Ltd. per share(10%)Dividend

Bal Pharma FAQs

What is Share Price of Bal Pharma ?

Bal Pharma share price is ₹88 As on 27 November, 2022 | 13:18

What is the Market Cap of Bal Pharma ?

The Market Cap of Bal Pharma is ₹138.1 Cr As on 27 November, 2022 | 13:18

What is the P/E ratio of Bal Pharma ?

The P/E ratio of Bal Pharma is 42.7 As on 27 November, 2022 | 13:18

What is the PB ratio of Bal Pharma ?

The PB ratio of Bal Pharma is 2.4 As on 27 November, 2022 | 13:18

Q2FY23
Open Demat Account